Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty.

Abbott Laboratories ABT reported second-quarter 2025 adjusted earnings per share (EPS) of $1.26, which beat the Zacks Consensus Estimate by 0.8%. The figure improved 10.5% from the prior-year ...

It is hard to get excited after looking at Abbott Laboratories' (NYSE:ABT) recent performance, when its stock has declined 5.8% over the past month. However, a closer look at its sound financials ...

Abbott Laboratories (NYSE:ABT) is included among the 10 Oversold Dividend Stocks to Buy According to Hedge Funds. The company reported strong earnings in the second quarter of 2025. It posted revenue ...

Jayson Bedford from Raymond James set a target price of $142.0 on 04/17/2025 $ABT Congressional Stock Trading Members of Congress have traded $ABT stock 13 times in the past 6 months.

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Sanford C. Bernstein raised their price target on shares of Abbott Laboratories from $133.00 to $138.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th.

The stock was sold at an average price of $133.82, for a total value of $12,199,967.94. Following the sale, the executive vice president now owns 71,928 shares of the company’s stock, valued at ...

Conversely, if the dividend payment decreases, so will the yield. ABT Price Action: Shares of Abbott Laboratories gained 0.9% to close at $127.96 on Monday. Read More: ...